{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T21:34:37Z","timestamp":1771364077267,"version":"3.50.1"},"reference-count":20,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100002855","name":"Ministry of Science and Technology of the People's Republic of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002855","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Antimicrobial Agents"],"published-print":{"date-parts":[[2019,11]]},"DOI":"10.1016\/j.ijantimicag.2019.06.002","type":"journal-article","created":{"date-parts":[[2019,6,11]],"date-time":"2019-06-11T02:19:35Z","timestamp":1560219575000},"page":"642-646","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Synergistic activities of clofazimine with moxifloxacin or capreomycin against Mycobacterium tuberculosis in China"],"prefix":"10.1016","volume":"54","author":[{"given":"Guilian","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhengquan","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haican","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li-li","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Machao","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Donglei","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiuqin","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhiguang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2258-3599","authenticated-orcid":false,"given":"Ruibai","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kanglin","family":"Wan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"Suppl 2","key":"10.1016\/j.ijantimicag.2019.06.002_bib0001","doi-asserted-by":"crossref","first-page":"S228","DOI":"10.1093\/infdis\/jir858","article-title":"Drug-resistant tuberculosis\u2013current dilemmas, unanswered questions, challenges, and priority needs","volume":"205","author":"Zumla","year":"2012","journal-title":"J Infect Dis"},{"key":"10.1016\/j.ijantimicag.2019.06.002_bib0002","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1016\/S0140-6736(10)60410-2","article-title":"Multidrug-resistant and extensively drug-resistant tuberculosis: a threat to global control of tuberculosis","volume":"375","author":"Gandhi","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.ijantimicag.2019.06.002_bib0003","unstructured":"World health organization. Global tuberculosis report 2016 [J]. 2016."},{"key":"10.1016\/j.ijantimicag.2019.06.002_bib0004","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/S1473-3099(13)70025-2","article-title":"Alignment of new tuberculosis drug regimens and drug susceptibility testing: a framework for action","volume":"13","author":"Wells","year":"2013","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.ijantimicag.2019.06.002_bib0005","first-page":"6","article-title":"B663 in the treatment of leprosy. Preliminary report of a pilot trial","volume":"33","author":"Browne","year":"1962","journal-title":"Lepr Rev"},{"key":"10.1016\/j.ijantimicag.2019.06.002_bib0006","unstructured":"World health organization. Companion handbook to the WHO guidelines for the programmatic management of drug-resistant tuberculosis. World Health Organization, 20 Avenue Appia, Geneva 27, Switzerland. WHO\/HTM\/TB\/2014.11."},{"key":"10.1016\/j.ijantimicag.2019.06.002_bib0007","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1093\/jac\/dkr444","article-title":"Clofazimine: current status and future prospects","volume":"67","author":"Cholo","year":"2012","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2019.06.002_bib0008","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.ijantimicag.2014.09.012","article-title":"In vitro synergistic activity of clofazimine and other antituberculous drugs against multidrug-resistant Mycobacterium tuberculosis isolates","volume":"45","author":"Zhang","year":"2015","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2019.06.002_bib0009","series-title":"Policy guidance on drug-susceptibility testing (DST) of second-line antituberculosis drugs (WHO\/HTM\/TB\/2008.392)","year":"2008"},{"key":"10.1016\/j.ijantimicag.2019.06.002_bib0010","unstructured":"World Health Organization. 2012Updated critical concentrations for first-line and second-line DST (as of May 2012)."},{"key":"10.1016\/j.ijantimicag.2019.06.002_bib0011","doi-asserted-by":"crossref","first-page":"e84065","DOI":"10.1371\/journal.pone.0084065","article-title":"Antimicrobial susceptibility of standard strains of nontuberculous mycobacteria by microplate Alamar Blue assay","volume":"8","author":"Li","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.ijantimicag.2019.06.002_bib0012","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/j.tube.2013.09.001","article-title":"Fast detection of drug interaction in Mycobacterium tuberculosis by a checkerboard resazurin method","volume":"93","author":"Caleffi-Ferracioli","year":"2013","journal-title":"Tuberculosis (Edinb)"},{"key":"10.1016\/j.ijantimicag.2019.06.002_bib0013","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/0065-2571(84)90007-4","article-title":"Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors","volume":"22","author":"Chou","year":"1984","journal-title":"Adv Enzyme Regul"},{"key":"10.1016\/j.ijantimicag.2019.06.002_bib0014","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/jac\/dkg301","article-title":"Synergy, antagonism, and what the chequerboard puts between them","volume":"52","author":"Odds","year":"2003","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2019.06.002_bib0015","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.ijantimicag.2014.11.017","article-title":"Combination of amikacin and doxycycline against multidrug-resistant and extensively drug-resistant tuberculosis","volume":"45","author":"Gonzalo","year":"2015","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2019.06.002_bib0016","doi-asserted-by":"crossref","first-page":"2729","DOI":"10.1128\/AAC.36.12.2729","article-title":"Antimicrobial activities of clofazimine and B669 are mediated by lysophospholipids","volume":"36","author":"Van Rensburg","year":"1992","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2019.06.002_bib0017","doi-asserted-by":"crossref","first-page":"e4009","DOI":"10.1371\/journal.pone.0004009","article-title":"Clofazimine inhibits human Kv1.3 potassium channel by perturbing calcium oscillation in T lymphocytes","volume":"3","author":"Ren","year":"2008","journal-title":"PLoS One"},{"key":"10.1016\/j.ijantimicag.2019.06.002_bib0018","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1097\/00002030-199703110-00008","article-title":"Clarithromycin and ethambutol with or without clofazimine for the treatment of bacteremic Mycobacterium avium complex disease in patients with HIV infection","volume":"11","author":"Chaisson","year":"1997","journal-title":"AIDS"},{"key":"10.1016\/j.ijantimicag.2019.06.002_bib0019","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/S1473-3099(10)70139-0","article-title":"Best drug treatment for multidrug-resistant and extensively drug-resistant tuberculosis","volume":"10","author":"Caminero","year":"2010","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.ijantimicag.2019.06.002_bib0020","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1159\/000226425","article-title":"Differences in cell wall thickness between resistant and nonresistant strains of Mycobacterium tuberculosis: using transmission electron microscopy","volume":"55","author":"Velayati","year":"2009","journal-title":"Chemotherapy"}],"container-title":["International Journal of Antimicrobial Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857919301438?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857919301438?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T17:33:24Z","timestamp":1760376804000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924857919301438"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11]]},"references-count":20,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019,11]]}},"alternative-id":["S0924857919301438"],"URL":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2019.06.002","relation":{},"ISSN":["0924-8579"],"issn-type":[{"value":"0924-8579","type":"print"}],"subject":[],"published":{"date-parts":[[2019,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Synergistic activities of clofazimine with moxifloxacin or capreomycin against Mycobacterium tuberculosis in China","name":"articletitle","label":"Article Title"},{"value":"International Journal of Antimicrobial Agents","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2019.06.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. and International Society of Chemotherapy. All rights reserved.","name":"copyright","label":"Copyright"}]}}